uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients
with severe disorders.
We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach.
“uniQure congratulates the Charité University Clinic in Berlin, Germany, and Professor Elisabeth Steinhagen-Thiessen on their announcement of the first patient treated with Glybera as a commercially-available gene therapy. uniQure recognizes the achievement by our commercialization partner Chiesi Farmaceutici, as well as the dedication of the uniQure researchers and employees, past and present, who contributed to this historic milestone.”
uniQure Announces Conference Call and Webcast to Discuss Third Quarter Financial Results and Corporate Update
uniQure to Present at the Jefferies 2015 Global Healthcare
Positive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure’s Novel AAV5-Based Gene Therapy